接受他汀类药物治疗的高级别非肌肉浸润性膀胱癌患者HMG共还原酶表达及对膀胱内卡介苗-谷氨酰胺的反应

IF 1.4 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Scottish Medical Journal Pub Date : 2024-02-01 Epub Date: 2023-11-13 DOI:10.1177/00369330231213935
Jamie Krishnan, Andrew Symington, Neil Kernohan, Suan Bray, Allison Robertson, Ghulam Nabi
{"title":"接受他汀类药物治疗的高级别非肌肉浸润性膀胱癌患者HMG共还原酶表达及对膀胱内卡介苗-谷氨酰胺的反应","authors":"Jamie Krishnan, Andrew Symington, Neil Kernohan, Suan Bray, Allison Robertson, Ghulam Nabi","doi":"10.1177/00369330231213935","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cardiovascular disease affects over 7 million people in the UK and statins are often prescribed to mitigate cardiovascular risks. The effect of statins on a number of cancers is debated and their effect on Bacillus Calmette-Guérin (BCG) responsiveness in non-muscle invasive urinary bladder cancer (NMIBC) is not fully understood.</p><p><strong>Aims: </strong>This study aims to explore the difference in HMG Co-A reductase (HMGCR) expression in NMIBC on immunochemistry in BCG responders and non-responders while on statins.</p><p><strong>Method: </strong>Three hundred and thirty-two cases of intravesical BCG treatment for high-risk NMIBC between November 2003 and December 2017 were identified. Patients taking statins for at least 12 months before the diagnosis of NIMBC and with a follow-up of at least 5 years were included. They were divided into BCG responders and non-responders. Tumour tissue from these patients was immunohistochemically stained and quantitative image analysis carried out to assess and compare HMGCR expression in the groups.</p><p><strong>Results & conclusion: </strong>This study showed a differential expression of HMGCR in responders vs. non-responders to BCG for high-risk NMIBC on statins. This data should form the basis of a further research and multi-centre study in a larger cohort, using HMGCR as a biomarker of response in patients on statins.</p>","PeriodicalId":21683,"journal":{"name":"Scottish Medical Journal","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"HMG co-reductase expression and response to intravesical Bacillus Calmette-Guérin in patients with high grade non-muscle invasive urinary bladder cancer receiving statins.\",\"authors\":\"Jamie Krishnan, Andrew Symington, Neil Kernohan, Suan Bray, Allison Robertson, Ghulam Nabi\",\"doi\":\"10.1177/00369330231213935\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Cardiovascular disease affects over 7 million people in the UK and statins are often prescribed to mitigate cardiovascular risks. The effect of statins on a number of cancers is debated and their effect on Bacillus Calmette-Guérin (BCG) responsiveness in non-muscle invasive urinary bladder cancer (NMIBC) is not fully understood.</p><p><strong>Aims: </strong>This study aims to explore the difference in HMG Co-A reductase (HMGCR) expression in NMIBC on immunochemistry in BCG responders and non-responders while on statins.</p><p><strong>Method: </strong>Three hundred and thirty-two cases of intravesical BCG treatment for high-risk NMIBC between November 2003 and December 2017 were identified. Patients taking statins for at least 12 months before the diagnosis of NIMBC and with a follow-up of at least 5 years were included. They were divided into BCG responders and non-responders. Tumour tissue from these patients was immunohistochemically stained and quantitative image analysis carried out to assess and compare HMGCR expression in the groups.</p><p><strong>Results & conclusion: </strong>This study showed a differential expression of HMGCR in responders vs. non-responders to BCG for high-risk NMIBC on statins. This data should form the basis of a further research and multi-centre study in a larger cohort, using HMGCR as a biomarker of response in patients on statins.</p>\",\"PeriodicalId\":21683,\"journal\":{\"name\":\"Scottish Medical Journal\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2024-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Scottish Medical Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/00369330231213935\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/11/13 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scottish Medical Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/00369330231213935","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/13 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

背景:在英国,心血管疾病影响着超过700万人,他汀类药物经常被用于降低心血管风险。他汀类药物对许多癌症的影响存在争议,其对非肌肉浸润性膀胱癌(NMIBC)中卡介苗(BCG)反应性的影响尚不完全清楚。目的:本研究旨在探讨卡介苗应答者和他汀类药物无应答者NMIBC免疫化学中HMG Co-A还原酶(HMGCR)表达的差异。方法:对2003年11月至2017年12月间采用卡介苗膀胱内治疗高危NMIBC病例332例进行分析。患者在确诊NIMBC前服用他汀类药物至少12个月,随访至少5年。他们被分为卡介苗应答者和无应答者。对这些患者的肿瘤组织进行免疫组织化学染色,并进行定量图像分析,以评估和比较各组HMGCR的表达。结果与结论:本研究显示,在接受他汀类药物治疗的高危NMIBC患者中,HMGCR在卡介苗应答者和无应答者中存在差异表达。这些数据应该成为进一步研究和更大队列多中心研究的基础,使用HMGCR作为他汀类药物患者反应的生物标志物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
HMG co-reductase expression and response to intravesical Bacillus Calmette-Guérin in patients with high grade non-muscle invasive urinary bladder cancer receiving statins.

Background: Cardiovascular disease affects over 7 million people in the UK and statins are often prescribed to mitigate cardiovascular risks. The effect of statins on a number of cancers is debated and their effect on Bacillus Calmette-Guérin (BCG) responsiveness in non-muscle invasive urinary bladder cancer (NMIBC) is not fully understood.

Aims: This study aims to explore the difference in HMG Co-A reductase (HMGCR) expression in NMIBC on immunochemistry in BCG responders and non-responders while on statins.

Method: Three hundred and thirty-two cases of intravesical BCG treatment for high-risk NMIBC between November 2003 and December 2017 were identified. Patients taking statins for at least 12 months before the diagnosis of NIMBC and with a follow-up of at least 5 years were included. They were divided into BCG responders and non-responders. Tumour tissue from these patients was immunohistochemically stained and quantitative image analysis carried out to assess and compare HMGCR expression in the groups.

Results & conclusion: This study showed a differential expression of HMGCR in responders vs. non-responders to BCG for high-risk NMIBC on statins. This data should form the basis of a further research and multi-centre study in a larger cohort, using HMGCR as a biomarker of response in patients on statins.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Scottish Medical Journal
Scottish Medical Journal 医学-医学:内科
CiteScore
4.80
自引率
3.70%
发文量
42
审稿时长
>12 weeks
期刊介绍: A unique international information source for the latest news and issues concerning the Scottish medical community. Contributions are drawn from Scotland and its medical institutions, through an array of international authors. In addition to original papers, Scottish Medical Journal publishes commissioned educational review articles, case reports, historical articles, and sponsoring society abstracts.This journal is a member of the Committee on Publications Ethics (COPE).
期刊最新文献
Pancreatic insulinomas: Our 15-year surgical experience. Efficacy and outcomes of a highland prehospital trauma response team. Ribosome-binding protein-1 (RRBP1) expression in prostate carcinomas and its relationship with clinicopathological prognostic factors. A pilot study of performance enhancement coaching for newly appointed urology registrars. Optimising the use of colonoscopy to improve risk stratification for colorectal cancer in symptomatic patients: A decision-curve analysis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1